- Facing pharmacy trends for the remainder of the year
- Senate passes Drug Quality and Security Act
- Award-winning McKesson Patient Relationship Solutions on display at McKesson ideaShare 2013
- FDA approves Plan B One-Step OTC switch
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
DARMSTADT, Germany — Merck KGaA has finished enrolling patients in a late-stage clinical study of a drug for Parkinson's disease, the German drug maker said.
Merck KGaA, which is a separate company from U.S.-based Merck & Co. and operates in the United States under the name EMD, said 549 patients with mid- to late-stage Parkinson's had enrolled in the phase-3 "SETTLE" study of safinamide. The study is designed to evaluate the drug's safety and efficacy as an add-on therapy to levodopa, a common treatment for Parkinson's.
The study is part of a broader program for the drug and will last for six months.